Interrogating host immunity to predict treatment response in inflammatory bowel disease

Area of Science:

• Immunology
• Gastroenterology
• Pharmacology

Background:

• Inflammatory bowel disease (IBD) treatment landscape is rapidly evolving with novel immunomodulatory drugs.
• Current therapies include agents targeting leukocyte trafficking (vedolizumab), cytokines (ustekinumab), and signaling pathways (tofacitinib).
• Despite advancements, primary and secondary loss of response necessitates personalized treatment strategies.

Purpose of the Study:

• To review the complexity of mucosal immune responses in IBD pathogenesis.
• To explore how current and emerging analytical platforms can stratify patients for individualized IBD therapy.
• To address the need for precision medicine in IBD management.

Main Methods:

• Review of current literature on IBD pathogenesis and therapeutic targets.
• Analysis of novel drug classes and their mechanisms of action.
• Discussion of advanced analytical platforms for immune profiling.

Main Results:

• Emergence of new drug classes targeting specific immune pathways in IBD.
• Limitations of current clinical stratification for predicting treatment response.
• Potential of high-resolution immune profiling technologies for personalized medicine.

Conclusions:

• Personalized medicine approaches are crucial for optimizing IBD treatment efficacy.
• Advanced analytical platforms like molecular endoscopy and transcriptomics show promise for patient stratification.
• Challenges in scalability and accessibility must be overcome for widespread clinical utility.